HAE vs HOLX

For growth investors, Haemonetics Corporation (HAE) is the stronger pick with 4.

0% revenue growth year-over-year, versus 1. 7% for Hologic, Inc. (HOLX). Haemonetics Corporation (HAE) offers the better valuation at 15. 9x trailing P/E (10. 6x forward), making it the more compelling value choice. Analysts rate Haemonetics Corporation (HAE) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Haemonetics Corporation (HAE) is the cheapest at 15.

9x versus Hologic, Inc. at 30. 5x. On forward P/E, Haemonetics Corporation is actually cheaper at 10. 6x.

Over the past 5 years, Hologic, Inc.

(HOLX) delivered a total return of +16. 7%, compared to -14. 3% for Haemonetics Corporation (HAE). Over 10 years, the gap is even starker: HOLX returned +125. 4% versus HAE's +89. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 41β versus Haemonetics Corporation's 0. 48β — meaning HAE is approximately 16% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Hologic, Inc. (HOLX) carries a lower debt/equity ratio of 52% versus 149% for Haemonetics Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Haemonetics Corporation (HAE) is pulling ahead at 4.

0% versus 1. 7% for Hologic, Inc. (HOLX). On earnings-per-share growth, the picture is similar: Haemonetics Corporation grew EPS 44. 5% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, HAE leads at 11. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hologic, Inc.

(HOLX) is the more profitable company, earning 13. 8% net margin versus 12. 3% for Haemonetics Corporation — meaning it keeps 13. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HOLX leads at 17. 4% versus 16. 3% for HAE. At the gross margin level — before operating expenses — HOLX leads at 61. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Haemonetics Corporation (HAE) trades at 10.

6x forward P/E versus 17. 2x for Hologic, Inc. — 6. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HAE: 60. 7% to $84. 60.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Hologic, Inc.

(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41), +125. 4% 10Y return). Both have compounded well over 10 years (HOLX: +125. 4%, HAE: +89. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: HAE is a small-cap deep-value stock; HOLX is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.